A phase3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects With Subclinical Atherosclerosis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 543 participants.

Also called NCT02546323

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 543 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02546323
Other papers using this trial's data
  • Rosuvastatin Slows Progression of Carotid Intima-Media Thickness: The METEOR-China Randomized Controlled Study Stroke, 2022-10 DOI, PubMed 36017704, PMC9508961 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02546323. Randomized; quadruple masking; primary purpose treatment. Start 2015-09-17 (actual); primary completion 2019-01-29 (actual). Results posted on 2019-12-11.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A phase3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects With Subclinical Atherosclerosis
Condition
Atherosclerosis
Intervention (Drug)
Rosuvastatin
Intervention (Drug)
Placebo
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct02546323
Content hash
32e7d1e0fc60bb66922923da0e7ed511af81626520a93664f9e6e36325d88fca